Changes in the in vitro pharmacodynamic properties of metoprolol in atria isolated from spontaneously hypertensive rats

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 3, 2007, Pages 161-165

  Di Verniero, Carla ^a   Höcht, Christian ^a   Opezzo, Javier A W ^a   Taira, Carlos A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Cardiac hypertrophy; Chronotropic effect; Dissociation constant; Inverse agonist activity; Metoprolol; Spontaneously hypertension

Indexed keywords

METOPROLOL; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHRONOTROPISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISSOCIATION CONSTANT; DRUG ACTIVITY; DRUG EFFECT; HEART ATRIUM; HEART VENTRICLE; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; MALE; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICAL SIGNIFICANCE; WISTAR KYOTO RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART; HEART ATRIA; HEART RATE; LINEAR MODELS; METOPROLOL; MYOCARDIAL CONTRACTION; NOREPINEPHRINE; ORGAN SIZE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; VASOCONSTRICTOR AGENTS;

EID: 33846447403     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04566.x     Document Type: Article

References (30)

1. Limas C, Limas CJ. Reduced number of β-adrenergic receptors in the myocardium of spontaneously hypertensive rats. Biochem. Biophys. Res. Commun. 1978; 83: 710-14.
2. Höcht C, Di Verniero C, Opezzo JAW, Taira CA. In vivo and in vitro pharmacodynamic properties of metoprolol in aortic coarctated rats. Pharmacol. Res. 2003; 47: 181-8.
3. Woodcock EA, Funder JW, Johnston CI. Decreased cardiac badrenoceptors in hypertensive rats. Clin. Exp. Pharmacol. Physiol. 1978; 5: 545-50.
4. Michel MC, Brodde OE, Insel PA. Are cardiac G-proteins altered in rat models of hypertension. Hypertension 1993; 11: 355-63.
5. Takata Y, Kato H. Adrenoceptors in SHR. Alterations in binding characteristics and intracellular signal transduction pathways. Life Sci. 1996; 58: 91-106.
6. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S. Inverse agonist activities of β-adrenoceptor antagonists in rat myocardium. Br. J. Pharmacol. 1999; 127: 895-902.
7. Gurdal H. Inverse agonism at β-adrenergic receptors: Therapeutic implications. Expert Rev. Neurother. 2002; 2: 261-9.
8. Maack C, Cremers B, Flesh M, Höper A, Südkamp M, Böhm M. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br. J. Pharmacol. 2000; 130: 1131-9.
9. Atkins FL, Bing OHL, Di Mauro PG, Conrad CH, Robinson KG, Brooks WW. Modulation of left and right ventricular β-adrenergic receptors from spontaneously hypertensive rats with left ventricular hypertrophy and failure. Hypertension 1995; 26: 78-82.
10. Saragoca M, Tarazi R. Impaired cardiac contractile response to isoproterenol in the spontaneously hypertensive rat. Hypertension 1981; 3: 380-5.
11. Habuchi Y, Lu LL, Okamoto S et al. Decreased sensitivity to beta-adrenergic stimulation of the ventricular cells isolated from the spontaneously hypertensive rat heart. Clin. Exp. Pharmacol. Physiol. Suppl. 1995; 22: S105-6.
12. Yamada S, Ishima T, Tomita T, Hayashi M, Okada T, Hayashi E. Alterations in cardiac alpha and beta adrenoceptors during the development of spontaneous hypertension. J. Pharmacol. Exp. Ther. 1984; 228: 454-60.
13. Höcht C, Di Verniero C, Opezzo JAW, Taira CA. Pharmacokinetic- pharmacodynamic properties of metoprolol in chronic aortic coarctated rats. Naunyn Schmiedebergs Arch. Pharmacol. 2004; 370: 1-8.
14. National Research Council. Guide for the Care and Use of Laboratory Animals. A report of the Institute of Laboratory Animal Resource Committee on the Care and Use of Laboratory Animals. NIH publication no. 85-23. US Department of Health and Human Services, Washington, DC. 1985.
15. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurements with the folin phenol reagent. J. Biol. Chem. 1951; 193: 265-75.
16. Lew MJ, Angus JA. Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol. Sci. 1995; 16: 328-37.
17. Maie S, Ohusuku S, Katsushika S et al. Enhanced beta-adrenergic signal transduction in spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 1991; 56: 671-3.
18. Saragoca M, Tarazi RC. Impaired cardiac contractile response to isoproterenol in the spontaneously hypertensive rat. Hypertension 1981; 3: 380-5.
19. Tsunoda M, Takezawa K, Santa T et al. New approach for measurement of sympathetic nervous abnormality in conscious, spontaneously hypertensive rats. Jpn. J. Pharmacol. 2000; 83: 39-45.
20. Doggrell SA, Surman AJ. Functional beta-adrenoceptors in the left atrium of normotensive and hypertensive rats. J. Auton. Pharmacol. 1994; 14: 425-36.
21. Daeffler L, Landry Y. Inverse agonism at heptahelical receptors: Concept, experimental approach and therapeutic potential. Fundam. Clin. Pharmacol. 2000; 14: 73-87.
22. Maack C, Tyroller S, Schnabel P et al. Characterization of beta(1)-selectivity, adrenoceptor-Gs-protein interaction and inverse agonism of nebivolol in human myocardium. Br. J. Pharmacol. 2001; 132: 1817-26.
23. Varma DR. Ligand-independent negative chronotropic responses of rat and mouse right atria to β-adrenoceptor antagonists. Can. J. Physiol. Pharmacol. 1999; 77: 943-9.
24. Engelhardt S, Grimmer Y, Fan GH, Lohse MJ. Constitutive activity of the human beta(1)-adrenergic receptor in beta(1)-receptor transgenic mice. Mol. Pharmacol. 2001; 60: 629-31.
25. Abrahamsson T, Ek B, Nerme V. The beta 1- and beta 2-adrenoceptor affinity of atenolol and metoprolol. A receptor-binding study performed with different radioligands in tissues from the rat, the guinea pig and man. Biochem. Pharmacol. 1988; 37: 203-8.
26. Ahmed A. Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: Implications for beta-blocker use in older adults with heart failure. Eur. J. Heart Fail. 2003; 5: 709-15.
27. Metra M, Dei Cas L, di Lenarda A, Poole-Wilson P. Beta-blockers in heart failure: Are pharmacological differences clinically important? Heart Fail. Rev. 2004; 9: 123-30.
28. Xiao RP, Zhang SJ, Chakir K et al. Enhanced Gi signaling selectively negates β2-adrenergic receptor (AR)- but not β1-AR-mediated positive inotropic effect in myocytes from failing rat hearts. Circulation 2003; 108: 1633-9.
29. Milano CA, Allen LF, Rockman HA et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science 1994; 264: 582-6.
30. Samama P, Cotecchia S, Costa T, Lefkowitz RJ. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 1993; 268: 4625-36.